5 recruiting, 4 active not recruiting, 2 terminated, 1 completed. 14 Phase 2, 5 Phase 1, 1 Phase 3.
Follow adagrasib: new trials by email Literature Review of adagrasib trials Research Report on adagrasib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer Adagrasib, Biospecimen Collection, Computed Tomography - Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 2 | Not yet recruiting | Roswell Park Cancer Institute | 29 | 2026-10-15 | 2026-09-02 |
| A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies Adagrasib, Pembrolizumab, Cetuximab - Solid Tumors | Phase 2 | Recruiting | Mirati Therapeutics Inc. | 170 | 2026-05-06 | 2026-10-27 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations Cetuximab, Cemiplimab, Adagrasib - Metastatic Colorectal Cancer, KRAS G12C Mutations | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 31 | 2024-08-28 | 2026-06-26 |
| Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases Adagrasib, Stereotactic Radiosurgery - Non Small Cell Lung Cancer, NSCLC | Phase 2 | Recruiting | Ryan Gentzler, MD | 30 | 2024-08-06 | 2026-04-08 |
| Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Adagrasib - Advanced Cancer, Metastatic Cancer | Phase 2 | Active not recruiting | Mirati Therapeutics Inc. | 200 | 2024-02-01 | 2026-08-14 |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors BMS-986466, Adagrasib, Cetuximab - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2023-11-09 | 2025-07-22 |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status Adagrasib - NSCLC Stage IV, KRAS P.G12C | Phase 2 | Active not recruiting | ETOP IBCSG Partners Foundation | 68 | 2023-06-12 | 2026-09-03 |
| Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab Adagrasib, Adagrasib/Nivolumab - Resectable Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2023-03-21 | 2025-09-15 | |
| Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients avutometinib (VS-6766) and adagrasib - Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1 / Phase 2 | Completed | Verastem, Inc. | 12 | 2022-08-01 | 2026-07-02 |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 Adagrasib, Pembrolizumab - Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Mirati Therapeutics Inc. | 626 | 2020-12-02 | 2026-10-30 |
| Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies Vociprotafib, Pembrolizumab, Adagrasib - Metastatic Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 65 | 2020-06-09 | 2025-05-29 |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib - CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 50 | 2019-10-17 | 2026-10-30 |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 MRTX849, Pembrolizumab, Cetuximab - Advanced Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Mirati Therapeutics Inc. | 731 | 2019-01-15 | 2026-07-29 |
Carcinoma, Non-Small-Cell Lung (7) · Neoplasm Metastasis (5) · Lung Neoplasms (4) · Colorectal Neoplasms (3) · Neoplasms (2) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Colonic Neoplasms (1) · Pancreatic Neoplasms (1)
Mirati Therapeutics Inc. (4) · Alliance for Clinical Trials in Oncology (1) · Bristol-Myers Squibb (1) · City of Hope Medical Center (1) · ETOP IBCSG Partners Foundation (1) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1) · Ryan Gentzler, MD (1) · Sanofi (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Verastem, Inc. (1)
United States (13) · France (5) · Spain (5) · Australia (4) · Israel (4) · Italy (4) · South Korea (4) · Belgium (3) · Brazil (3) · Greece (3) · Japan (3) · Netherlands (3) · Poland (3) · Romania (3) · Taiwan (3)
Christine Parseghian, MD (1) · Grace K Dy (1) · Jarushka Naidoo (1) · Kristen Marrone (1) · MD Verastem (1) · Priscilla Brastianos, MD (1) · Ravi Salgia, MD (1) · Ryan Gentzler, MD, MS (1)
PMID 32479604, PMID 34161704, PMID 35167329, PMID 35404402, PMID 35658005, PMID 36546659, PMID 37099736, PMID 37327468, PMID 38579193
2023 (3), P30CA033572 (1), U10CA180821 (1)